Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Merit Medical SystemsMMSI +0.29%83 3-Year EBITDA Growth Rate is 20.50% as of Jun. 2026, which is 68% above its 10-year median of 12.20. GuruFocus rates MMSI with a GF Score™ of 83/100 and a GF Value™ of $95.95 (Fairly Valued). The stock has 2 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Merit Medical Systems ranks better than 66.23% on this metric.
During the past 12 months, Merit Medical Systems's average EBITDA Per Share Growth Rate was 19.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Merit Medical Systems was 90.20% per year. The lowest was -9.10% per year. And the median was 12.20% per year.
Merit Medical Systems (NAS:MMSI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Merit Medical Systems 3-Year EBITDA Growth Rate Related Terms
MMSI vs NVST, MMED, ICUI: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Merit Medical Systems's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merit Medical Systems 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Merit Medical Systems's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Merit Medical Systems's 3-Year EBITDA Growth Rate falls into.
Merit Medical Systems 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.50% mean?
Merit Medical Systems (MMSI) has a 3-Year EBITDA Growth Rate of 20.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Merit Medical Systems and its competitors. This is 68% above median its historical median of 12.20. According to the industry distribution chart, Merit Medical Systems ranks #233 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 33.8%.
Is Merit Medical Systems' 3-Year EBITDA Growth Rate too high?
Merit Medical Systems' current 3-Year EBITDA Growth Rate of 20.50% is 68% above median its 10-year median of 12.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Merit Medical Systems' value of 20.50% is 150% above this industry median. Based on the distribution chart, Merit Medical Systems ranks #233 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Merit Medical Systems has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merit Medical Systems' 3-Year EBITDA Growth Rate compare to NVST and MMED?
According to the Medical Devices & Instruments industry distribution chart, Merit Medical Systems ranks #233 out of 690 companies for 3-Year EBITDA Growth Rate. This puts Merit Medical Systems in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Merit Medical Systems' value of 20.50% is 150% above this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 8.20, Merit Medical Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merit Medical Systems's current 3-Year EBITDA Growth Rate of 20.50% is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Merit Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merit Medical Systems's current 3-Year EBITDA Growth Rate is 20.50%, which is 68% above median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merit Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Merit Medical Systems (MMSI) is currently considered Fairly Valued. The stock's GF Value™ is $95.95, compared to a current price of $90.77 — trading 5.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.50%, which is 68% above median its 10-year median of 12.20 and 150% above the Medical Devices & Instruments industry median of 8.20. Merit Medical Systems' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Merit Medical Systems (MMSI), the current 3-Year EBITDA Growth Rate is 20.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merit Medical Systems (MMSI) Overvalued in 2026?
Based on GuruFocus' analysis, Merit Medical Systems stock appears to be undervalued.
The current stock price of $90.77 is trading 5.4% below its estimated GF Value™ of $95.95.
GuruFocus considers Merit Medical Systems to be Fairly Valued.
Key valuation signals for MMSI:
3-Year EBITDA Growth Rate: 20.50% (68% above median its 10-year median of 12.20)
GF Value™: $95.95 vs. price of $90.77 (5.4% below fair value)
Industry Position: 150% above the Medical Devices & Instruments median (#233 of 690)
No single metric tells the full story. See the MMSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
83GF Score
Get the complete analysis for MMSI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMSI has been successfully added to your 
